Equities
Health CarePharmaceuticals and Biotechnology
  • Price (DKK)367.30
  • Today's Change-2.80 / -0.76%
  • Shares traded851.44k
  • 1 Year change-16.28%
  • Beta0.6274
Data delayed at least 15 minutes, as of Mar 03 2026 16:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Novozymes A/S is a Denmark-based biotechnology company engaged in the production and sale of industrial enzymes, microorganisms and biopharmaceutical ingredients. The Company operates in four geographical regions: Europe, Middle East & Africa (including Denmark), North America, Asia Pacific and Latin America. It develops and distributes solutions within the market areas agriculture, bioenergy, food & beverages, household care, leather, pharmaceuticals, forest products, textile and wastewater solutions. Novozymes operates through a range of partnerships with companies, such as Bayer and Syngenta in Agriculture and DSM and Adisseo in Animal Health & Nutrition..

  • Revenue in DKK (TTM)31.05bn
  • Net income in DKK4.36bn
  • Incorporated2000
  • Employees11.64k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Symrise AG37.26bn3.79bn79.88bn12.98k21.072.8813.152.143.633.6335.7326.570.63772.394.88392,117.306.535.148.006.0940.5737.9310.248.380.827413.000.392741.535.677.9640.4610.146.854.78
Yara International ASA99.64bn8.73bn83.36bn17.00k9.551.505.330.836651.3551.35586.44327.440.97243.499.56--8.535.5411.017.3528.2926.438.785.390.8859--0.323772.0112.666.159,671.4314.644.59-14.05
Ems Chemie Holding AG16.43bn3.79bn120.76bn2.76k31.877.1028.367.3519.7519.7585.6988.600.8193--5.92709,534.4019.0822.1021.8026.30--44.9623.2922.824.52--0.011787.59-5.40-0.77340.7015-2.65-12.19-4.12
Novozymes A/S31.05bn4.36bn154.54bn11.64k40.002.1417.864.989.329.3266.41174.010.26362.575.772,667,418.003.706.224.217.3753.9152.8714.0415.010.441812.040.216855.388.4517.2090.849.0130.144.32
Sika AG91.88bn8.56bn207.18bn33.71k24.203.7915.922.266.506.5052.3541.490.71983.905.35332,313.806.728.508.3710.5754.9452.959.3310.320.899810.830.452932.89-4.787.29-16.184.8323.318.16
Data as of Mar 03 2026. Currency figures normalised to Novozymes A/S's reporting currency: Danish Krone DKK

Institutional shareholders

16.84%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 04 Feb 202613.09m3.16%
Norges Bank Investment Managementas of 30 Jun 202511.12m2.68%
Pictet Asset Management SAas of 06 Feb 20267.94m1.92%
BlackRock Fund Advisorsas of 06 Feb 20266.02m1.45%
BlackRock Investment Management (UK) Ltd.as of 27 Feb 20265.72m1.38%
Fidelity Management & Research Co. LLCas of 31 Dec 20255.60m1.35%
APG Asset Management NVas of 31 Dec 20245.55m1.34%
Impax Asset Management Ltd.as of 30 Jan 20265.51m1.33%
Comgest SAas of 31 Dec 20255.30m1.28%
Geode Capital Management LLCas of 26 Feb 20263.97m0.96%
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.